The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ 505(b)(2) new drug application (NDA) for a ready-to-use oncology injectable, PEMRYDI RTU.

PEMRYDI RTU is indicated as an initial treatment, along with pembrolizumab and platinum chemotherapy, for metastatic non-squamous non-small cell lung cancer patients with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumour aberration.

In combination with cisplatin, the therapy has also been indicated for the initial treatment of malignant pleural mesothelioma patients whose disease is unresectable or who are not candidates for curative surgery.

Amneal Pharmaceuticals claimed that PEMRYDI RTU is the first and only ready-to-use presentation of pemetrexed for injection.

Amneal Pharmaceuticals subsidiary Amneal Biosciences senior vice-president Harsher Singh stated: “We believe PEMRYDI RTU, the first ready-to-use version of a key oncology injectable, will offer a meaningful advantage in this improved presentation.

“By eliminating formulation steps common with other pemetrexed products, we are improving provider efficiencies while reducing the risk of medication errors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This approval represents another high-value product for our growing injectables portfolio which we expect to launch with a J-code [a common healthcare procedure coding system identifier] for PEMRYDI RTU.”

With a J-code from the Centers for Medicare & Medicaid Services, PEMRYDI RTU is expected to be launched in the first quarter of 2024.

The product will be offered in 500mg/50mL,100mg/10mL and 1,000mg/100mL vial sizes.

Adverse effects reported while using PEMRYDI RTU have included renal failure, radiation recall, skin toxicity and myelosuppression [reduction in bone marrow activity].